ARQT - Arcutis Biotherapeutics: Interesting But Needs Cautious Approach Here
- Arcutis has an upcoming phase 3 data readout catalyst in 1Q 2021.
- Past data has been good, with a clear competitive difference.
- However, low cash and competition makes this a cautious investment, albeit with potential for high rewards.
For further details see:
Arcutis Biotherapeutics: Interesting, But Needs Cautious Approach Here